Associated Papers
PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers.
Hulse M et al.
Cancer Research, 2026
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.
Cantley J et al.
Nature Communications, 2022
36357397 (PubMed )
Supplement: 41467_2022_34562_MOESM6_ESM.xlsx › Sheet1
Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients.
Fernando TM et al.
Nature Communications, 2020
33144586 (PubMed )
Supplement: 41467_2020_19402_MOESM6_ESM.xlsx › Sheet1
Select a paper to view details